PALVELLA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
About Palvella Therapeutics
Pharmaceutical Preparations, SIC 2834
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for individuals suffering from serious, rare skin diseases and vascular malformations that lack approved treatments. The company utilizes its proprietary QTORIN drug development platform to produce topical therapies designed to penetrate deep skin layers. Its lead product candidate is QTORIN rapamycin, an anhydrous gel in clinical development for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Additionally, the company develops QTORIN pitavastatin to treat disseminated superficial actinic porokeratosis. Its target patient populations include individuals diagnosed with these rare dermatologic and vascular conditions.
The company is based in Wayne, Pennsylvania, where it maintains its principal executive offices. Its clinical development activities include studies conducted across specialized vascular anomaly centers located in the United States. Following a merger, it operates with Legacy Palvella as a wholly owned subsidiary.
Summary of the business section of Palvella Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PALVELLA THERAPEUTICS, INC.
- Headquarters
- Wayne, PA
- Address
- 353 W. Lancaster Avenue, Suite 200 19087
- Phone
- (484) 253-1461
- Website
- palvellatx.com
- Employees
- 29, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- PVLA
- Exchange
- Nasdaq
- IPO date
- Jan 2, 2015
- Shares outstanding
- 14M, Jul 31, 2026
- Public float
- $196.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-80 reverse, May 15, 2024; 1-for-80 reverse, Apr 23, 2024; 9-for-4, Dec 5, 2014
- SEC CIK
- 1583648
- CUSIP
- 697947109
- ISIN
- US6979471090
- LEI
- 254900AJDH8PAOOI5T33
- EIN
- 30-0784346
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Wes Kaupinen | President and CEO, Director | 1,607,228 |
| Kathleen Goin | Chief Operating Officer | 4,302 |
| Matthew E. Korenberg | CFO, Treasurer | 1,000 |
| Ashley Hartmann Kline | Chief Commercial Officer | – |
| Jeffrey S. Martini | Chief Scientific Officer | – |
| Palvella Therapeutics, Inc. | CFO and Treasurer | – |
| George M. Jenkins | Director | 174,192 |
| Christopher P. Kiritsy | Director | 250 |
| Matthew Pauls | Director | – |
| John Doux | Director | – |
| Tadd S. Wessel | Director | – |
| Elaine J. Heron | Director | 53,691 |
| Todd C. Davis | Director | 112,547 |
| James A. Geraghty | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Wesley HKaupinen | $3.40M | $57.10M | $1.98M | $126 | – |
| FY2024 Stephen Yoder | $1.43M | $1.38M | $1.20M | $14 | – |
| FY2024 Wesley HKaupinen | $5.15M | $4.55M | $1.20M | $14 | – |
| FY2023 Stephen Yoder | $1.36M | $553.95K | $717.24K | $18 | – |
| FY2022 Stephen Yoder | $2.06M | -$526.88K | $954.08K | $28 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 25, 2026, we had 29 full-time employees, of which two have Ph.Ds.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 16, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 12, 2024 | Name change | Name changed from PIERIS PHARMACEUTICALS, INC. to PALVELLA THERAPEUTICS, INC. |
| Aug 9, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 19, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 7, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 24, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 15, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 18, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 18, 2014 | Name change | Name changed from Marika Inc. to PIERIS PHARMACEUTICALS, INC. |
| Dec 18, 2014 | Auditor change | Change in certifying accountant (8-K Item 4.01) |